INFLAMMATORY BOWEL DISEASE

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

T Mimura¹, F Rizzello², U Helwig², G Poggioli², S Schreiber³, I C Talbot¹, R J Nicholls¹, P Gionchetti², M Campieri², M A Kamm¹

¹ Departments of Medicine, Surgery, and Pathology, St Mark’s Hospital, London, UK
² Departments of Internal Medicine, Gastroenterology, and Surgery, University of Bologna, Bologna, Italy
³ First Department of Medicine, Christian-Albrechts-University, Kiel, Germany

Correspondence to:
Correspondence to:
Professor M A Kamm
St Mark’s Hospital, Watford Rd, Harrow, Middlesex HA1 3UJ, UK; kamm{at}ic.ac.uk

Background: Ten to 15% of patients with pouchitis experience refractory or recurrent disease. The aim of this study was to evaluate the effectiveness of a single daily high dose probiotic preparation (VSL#3) in maintaining antibiotic induced remission, and quality of life (QOL), for one year in such patients.

Methods: Patients with pouchitis at least twice in the previous year or requiring continuous antibiotics, associated with a pouchitis disease activity index (PDAI) 7 (0 = perfect; 18 = worst), in whom remission was induced by four weeks of combined metronidazole and ciprofloxacin, were randomised to receive VSL#3 6 g or placebo once daily for one year or until relapse. Symptomatic, endoscopic, and histological evaluations were made before, and two and 12 months after randomisation or at the time of relapse. Remission was defined as a clinical PDAI 2 and endoscopic PDAI 1. Relapse was defined as an increased clinical PDAI score 2 and increased endoscopic PDAI score 3. QOL was assessed using the inflammatory bowel disease questionnaire (IBDQ).

Results: Thirty six patients were randomised: 20 to VSL#3 and 16 to placebo. Remission was maintained at one year in 17 patients (85%) on VSL#3 and in one patient (6%) on placebo (p<0.0001). The IBDQ score remained high in the VSL#3 group (p = 0.3) but deteriorated in the placebo group (p = 0.0005).

Conclusion: The once daily high dose probiotic VSL#3 is effective in maintaining antibiotic introduced remission for at least a year in patients with recurrent or refractory pouchitis. This is associated with a high level of quality of life.

Keywords: pouchitis; probiotics; quality of life; VSL#3

Abbreviations: IPAA, ileal pouch anal anastomosis; QOL, quality of life; IBDQ, inflammatory bowel disease questionnaire; PDAI, pouchitis disease activity index

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Harding, S. V., Fraser, K. G., Wykes, L. J. (2008). Probiotics Stimulate Liver and Plasma Protein Synthesis in Piglets with Dextran Sulfate-Induced Colitis and Macronutrient Restriction. J. Nutr. 138: 2129-2135 [Abstract] [Full Text]  
• Myllyluoma, E., Ahonen, A.-M., Korpela, R., Vapaatalo, H., Kankuri, E. (2008). Effects of Multispecies Probiotic Combination on Helicobacter pylori Infection In Vitro. CVI 15: 1472-1482 [Abstract] [Full Text]  
• Quigley, E. M M (2007). Probiotics in Irritable Bowel Syndrome: An Immunomodulatory Strategy?. J. Am. Coll. Nutr. 26: 684S-690S [Abstract] [Full Text]  
• Caballero-Franco, C., Keller, K., De Simone, C., Chadee, K. (2007). The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G315-G322 [Abstract] [Full Text]  
• McLaughlin, S. D, Clark, S. K, Nicholls, R J., Tekkis, P. P, Ciclitira, P. J (2006). Effective probiotic treatment is rarely cheap. BMJ 333: 1272-1272 [Full Text]  
• Marteau, P (2006). Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease?. Gut 55: 1692-1693 [Full Text]  
• Daniel, C., Poiret, S., Goudercourt, D., Dennin, V., Leyer, G., Pot, B. (2006). Selecting Lactic Acid Bacteria for Their Safety and Functionality by Use of a Mouse Colitis Model. Appl. Environ. Microbiol. 72: 5799-5805 [Abstract] [Full Text]  
• Marteau, P, Lemann, M, Seksik, P, Laharie, D, Colombel, J F, Bouhnik, Y, Cadiot, G, Soule, J C, Bourreille, A, Metman, E, Lerebours, E, Carbonnel, F, Dupas, J L, Veyrac, M, Coffin, B, Moreau, J, Abitbol, V, Blum-Sperisen, S, Mary, J Y (2006). Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842-847 [Abstract] [Full Text]  
• Kuhbacher, T, Ott, S J, Helwig, U, Mimura, T, Rizzello, F, Kleessen, B, Gionchetti, P, Blaut, M, Campieri, M, Folsch, U R, Kamm, M A, Schreiber, S (2006). Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55: 833-841 [Abstract] [Full Text]  
• Gaudier, E., Michel, C., Segain, J.-P., Cherbut, C., Hoebler, C. (2005). The VSL# 3 Probiotic Mixture Modifies Microflora but Does Not Heal Chronic Dextran-Sodium Sulfate-Induced Colitis or Reinforce the Mucus Barrier in Mice. J. Nutr. 135: 2753-2761 [Abstract] [Full Text]  
• Sherman, P. M., Johnson-Henry, K. C., Yeung, H. P., Ngo, P. S. C., Goulet, J., Tompkins, T. A. (2005). Probiotics Reduce Enterohemorrhagic Escherichia coli O157:H7- and Enteropathogenic E. coli O127:H6-Induced Changes in Polarized T84 Epithelial Cell Monolayers by Reducing Bacterial Adhesion and Cytoskeletal Rearrangements. Infect. Immun. 73: 5183-5188 [Abstract] [Full Text]  
• Grangette, C., Nutten, S., Palumbo, E., Morath, S., Hermann, C., Dewulf, J., Pot, B., Hartung, T., Hols, P., Mercenier, A. (2005). From The Cover: Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc. Natl. Acad. Sci. USA 102: 10321-10326 [Abstract] [Full Text]  
• Gionchetti, P, Lammers, K M, Rizzello, F, Campieri, M (2005). Probiotics and barrier function in colitis. Gut 54: 898-900 [Full Text]  
• Sturm, A., Rilling, K., Baumgart, D. C., Gargas, K., Abou-Ghazale, T., Raupach, B., Eckert, J., Schumann, Ralf. R., Enders, C., Sonnenborn, U., Wiedenmann, B., Dignass, A. U. (2005). Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling. Infect. Immun. 73: 1452-1465 [Abstract] [Full Text]  
• Furrie, E, Macfarlane, S, Kennedy, A, Cummings, J H, Walsh, S V, O'Neil, D A, Macfarlane, G T (2005). Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54: 242-249 [Abstract] [Full Text]  
• Bell, A J G, Nicholls, R J, Forbes, A, Ellis, H J, Ciclitira, P J (2004). Human lymphocyte stimulation with pouchitis flora is greater than with flora from a healthy pouch but is suppressed by metronidazole. Gut 53: 1801-1805 [Abstract] [Full Text]  
• (2004). Probiotics for gastrointestinal disorders. DTB 42: 85-88 [Abstract] [Full Text]  
• Ghosh, S, van Heel, D, Playford, R J (2004). Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut 53: 620-622 [Full Text]  
• (2004). Single-Dose VSL#3 Maintains Remission in Pouchitis. JWatch Gastroenterology 2004: 3-3 [Full Text]